Seagen Stock Forecast, Price & News

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last year. There are currently 1 sell rating, 6 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

Wall Street analysts have given Seagen a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seagen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Seagen saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,670,000 shares, an increase of 43.9% from the March 15th total of 2,550,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 3.2 days.
View Seagen's Short Interest.

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Seagen.

Seagen will be holding an earnings conference call on Thursday, April 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings data on Thursday, February, 11th. The biotechnology company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.81 by $0.09. The biotechnology company had revenue of $601.29 million for the quarter, compared to analyst estimates of $583.58 million. Seagen had a trailing twelve-month return on equity of 20.46% and a net margin of 25.34%. During the same period in the previous year, the firm posted $0.14 earnings per share.
View Seagen's earnings history.

Seagen's stock was trading at $104.51 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SGEN stock has increased by 39.2% and is now trading at $145.50.
View which stocks have been most impacted by COVID-19.

19 analysts have issued 1 year target prices for Seagen's stock. Their forecasts range from $129.00 to $254.00. On average, they anticipate Seagen's stock price to reach $185.36 in the next twelve months. This suggests a possible upside of 27.4% from the stock's current price.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of SGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Royal London Asset Management Ltd. (0.03%), State of Alaska Department of Revenue (0.02%), DnB Asset Management AS (0.02%), Louisiana State Employees Retirement System (0.01%), EFG Asset Management Americas Corp. (0.00%) and Addison Capital Co (0.00%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson and Vaughn B Himes.
View institutional ownership trends for Seagen.

SGEN stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., State of Alaska Department of Revenue, and Addison Capital Co. Company insiders that have sold Seagen company stock in the last year include Bros Advisors Lp Baker, Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Marc E Lippman, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

SGEN stock was bought by a variety of institutional investors in the last quarter, including DnB Asset Management AS, EFG Asset Management Americas Corp., NuWave Investment Management LLC, Royal London Asset Management Ltd., Louisiana State Employees Retirement System, Redpoint Investment Management Pty Ltd, and Fulton Bank N.A..
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $145.50.

Seagen has a market capitalization of $26.38 billion and generates $916.71 million in revenue each year. The biotechnology company earns $-158,650,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

Seagen employs 2,092 workers across the globe.

Seagen was founded in 1998.

The official website for Seagen is www.seattlegenetics.com.

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]